Dermira (DERM) Receiving Somewhat Favorable Press Coverage, Study Finds
Press coverage about Dermira (NASDAQ:DERM) has trended somewhat positive on Monday, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Dermira earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 44.9414953984057 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- Dermira (DERM) PT Lowered to $39.00 at Mizuho (americanbankingnews.com)
- Dermira Inc (DERM) CEO Thomas G. Wiggans Sells 5,000 Shares (americanbankingnews.com)
- Dermira (DERM) Given “Buy” Rating at Guggenheim (americanbankingnews.com)
- Dermira Inc (DERM) Given Average Recommendation of “Hold” by Brokerages (americanbankingnews.com)
- Dermira, Inc. breached its 50 day moving average in a Bullish Manner : DERM-US : December 12, 2017 (finance.yahoo.com)
DERM has been the subject of a number of analyst reports. Cantor Fitzgerald reiterated a “buy” rating and issued a $45.00 price objective on shares of Dermira in a research report on Monday, November 6th. Zacks Investment Research downgraded shares of Dermira from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. Leerink Swann restated an “outperform” rating and set a $41.00 price target (down previously from $47.00) on shares of Dermira in a research report on Tuesday, November 7th. Guggenheim started coverage on shares of Dermira in a research report on Tuesday, December 5th. They set a “buy” rating for the company. Finally, Mizuho restated a “buy” rating and set a $43.00 price target (up previously from $40.00) on shares of Dermira in a research report on Thursday, September 7th. Four research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $41.00.
In related news, CEO Thomas G. Wiggans sold 5,000 shares of the company’s stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $27.51, for a total transaction of $137,550.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eugene A. Bauer sold 7,500 shares of the company’s stock in a transaction dated Wednesday, October 11th. The stock was sold at an average price of $30.04, for a total transaction of $225,300.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 24,300 shares of company stock valued at $685,630. Insiders own 13.30% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Dermira (DERM) Receiving Somewhat Favorable Press Coverage, Study Finds” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.watchlistnews.com/dermira-derm-receiving-somewhat-favorable-press-coverage-study-finds/1770446.html.
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.